Toru Yoshino, MD

Excited to share our latest review article on TP53-mutated AML/MDS. Heartfelt thanks to our wonderful mentor Dr. Konopleva for her constant support, encouragement, and guidance. @mkonople @AndrewGutwein @jmsongmd @jmcchiefs @shwetad96 frontiersin.org/journals/oncol…

Findings move us beyond who is eligible to how to intervene equitably, and strategically. 🔑Race/ethnicity influences the likelihood of belonging to certain marginalized groups, highlighting structural and intersectional pathways to disparity (vs. race alone as a direct cause).

One-size-fits-all interventions may not work. 🔹 Poor access → free screening programs, mobile units, system-level outreach 🔹 Healthier groups → shared decision-making support, simplified workflows, making screening easy rather than urgent

We assume lung cancer screening disparities are driven mainly by inequitable access Our study shows the story is more nuanced Using LCA, we found not only marginalized groups with poor access, but also “healthy” groups with low screening rates vs. people with COPD/poor health

🔗 sciencedirect.com/science/articl… Huge thanks to my mentors 🙌 @hkato01 @SaeMorita, and Dr. Zinner!

Why do lung cancer screening rates remain low? 📊Socioeconomic & geographic disparities matter.
Using multiple-group latent class analysis, we identified specific marginalized groups with low screening rates. 🎯Focusing resources on these groups may reduce lung cancer mortality.

Hello #MedTwitter! I’m Kohei Chida — research fellow @RoswellPark, NY, applying to #GenSurg for #Match2026 ✅ 🇯🇵 MD & General Surgery training in Japan 🎾 Tennis | 🥾 Hiking | ✈️ Traveling | 🏈 Bills Let's Connect! 📌 AAMC ID: 15933404 🔗 LinkedIn: bit.ly/4fRUXwZ 🔗 NIH MyBibliography: bit.ly/45zZZLn

Congratulations Rika! I’m so proud of you! Welcome to Jacobi💪

pCR has been used as a surrogate marker for drug approval in high-risk early stage TNBC. Further study in surrogate marker for drug approval in early-stage TNBC is still warranted.

My research article got published! We evaluated pathological complete response (pCR) for long-term survival in TNBC. There is no strong evidence to support the use of pCR as a surrogate marker for long-term survival at trial level. academic.oup.com/jncics/advance…

@jmsongmd Thanks Junmin!

@TYoshiMD @TFujii_MD Congrats Toru!

Now presenting my poster on racial disparities in lobular cell carcinoma! Always a pleasure to see my mentors, @TFujii_MD and Stan Lipkowitz. #SABCS24

@AndrewGutwein Thank you for your all support! Jacobi strong 💪

Congrats Toru! Jacobi strong!

I’ll be presenting my research poster tomorrow at noon at SABCS! Stop by if you’re interested 😊 #SABCS24

Learning so much from the #WCLC2024! From grant application, early career advices, and connecting with mentors/legends! 👇Will be presenting tomorrow and Monday PT01.01.04: Sun 18:46-19:15 P3.01E: Mon 12:00-14:00 Thank you @chulkimMD! Jacobi Strong! @AndrewGutwein @LeiDeng3

Had a great meeting with Dr. Yoshino!!! He is a great Japanese physician and researcher simultaneously! He kindly told me how fun the resident life in NY is🇺🇸 I will up my game to reach a wonderful life in US like him🔥 @TYoshiMD @AndrewGutwein

New academic year, new chiefs! We're so excited to introduce ourselves to the #MedTwitter world as the new Chief residents of @JacobiHosp @EinsteinMed IM residency program for the academic year 2024-25! @AndrewGutwein

IM Class of 2027, welcome to Jacobi!

👏👏👏 here’s the list of abstract titles from @SocietyGIM website

Hi! #MedTwitter, I’m Agun Nukaya from Japan, working at US-Naval Hospital Iwakuni⚓️ I’m applying to #internalmedicine in #Match2025🤞 Love to learn interesting physical examinations and do Gram stain 🦠 🧫 Hyped to connect with future colleagues and mentors🔥